KEYTRUDA for Hodgkin Lymphoma


Questions to ask your doctor about Hodgkin Lymphoma

Here are some questions you may want to ask your doctor or specialist about Hodgkin Lymphoma.

These will help you understand your diagnosis and treatment, and any future implications.

Questions to ask after diagnosis

  • Whay type of lymphoma do I have? What does this mean exactly?
  • What stage is the lymphoma? Can you explain what this means?
  • Has my lymphoma spread? If so, how far?
  • Will I need surgery? Will that remove all the cancer?
  • Are there support services available?
  • Who will be leading my overall treatment?

Questions to ask about treatments

  • Will I require treatment other than surgery? What do you recommend?
  • What are the goals of these treatments?
  • What is the success rate of these treatments?
  • Are there any side effects of my treatments? How can I manage these?
  • How long will the treatments last for?
  • Are there any clinical trials available?

Questions to ask after treatment

  • Will I have a scar from surgery?
  • Will the cancer return? Can I do anything to prevent it coming back?
  • Will this make me a higher risk for other cancer types?
  • How often will I need to see you after treatment?
  • Does this make my family at higher risk for developing Hodgkin Lymphoma?

Questions to ask your insurer

There are a number of ways to access treatments that are not funded by the government. These are outlined on the Access KEYTRUDA page. Below are a few questions you can ask your health, life or trauma insurance company if you’ve taken out a policy.

  1. Does my policy cover me for unfunded cancer treatment?
  2. Does my policy cover me for my entire course of treatment? If not, which aspects of my treatment am I covered for?
  3. How does it work exactly?

QUESTIONS FOR YOUR DOCTOR

What is Hodgkin Lymphoma

How to access KEYTRUDA

How KEYTRUDA works


KEYTRUDA (pembrolizumab) 50mg powder for infusion
KEYTRUDA is a Prescription Only Medicine Use: KEYTRUDA is used in the treatment of melanoma which cannot be removed by surgery alone or when it has spread to multiple sites in the body. In the treatment of a kind of lung cancer called non-small cell lung cancer (NSCLC). In the treatment of classical Hodgkin Lymphoma (cHL). In the treatment of urothelial carcinoma, including bladder cancer. Side effects: Immune-mediated side effects including inflammation of the lungs, colon, liver, kidneys, pituitary gland, brain, eye, muscles, nervous system, pancreas, and heart, thyroid disorders, type 1 diabetes mellitus. Severe skin reactions including Steven-Johnson syndrome and toxic epidermal necrolysis. Severe infusion reactions including hypersensitivity and anaphylaxis. Transplant recipients: rejection of a transplanted organ, graft-versus- host-disease (in people with a bone marrow transplant using donor cells). Very common side effects include diarrhea, nausea, itching, rash, joint pain, back pain, feeling tired, cough, patches of discoloured skin, stomach pain, decreased levels of sodium in blood. Tiredness, nausea, vomiting, diarrhea, constipation, shortness of breath, rash, itching, headache, hair loss, and, infections of the upper respiratory tract were reported when given in combination with chemotherapy. You may experience more than one side effect at the same time. All medicines have risks and benefits. Talk to your doctor to see if KEYTRUDA is right for you. KEYTRUDA is a funded medicine for melanoma patients– restrictions apply. KEYTRUDA is an unfunded medicine for NSCLC, cHL and urothelial carcinoma patients. Ask your health professional the cost of the medicine and any other medical fees that may apply. Use only as directed and if symptoms continue or you have side effects, see your doctor, pharmacist, or health professional. Based on data sheet prepared 10 April 2018. Marketed by: Merck Sharp & Dohme (New Zealand) Limited, Newmarket, Auckland. For additional product information, consult the Consumer Medicine Information (CMI), available on request, phone 0800 500 673 or refer to the Medsafe website www.medsafe.govt.nz.

This site is intended for New Zealand residents.

References to support this are available on request.

MSD recommends people always seek the medical advice of their healthcare professional.

Copyright © 2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, USA. All rights reserved.

Copyright © 2018 Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland. All rights reserved.

ONCO-1250168-0032 First Issued November 2017 TAPS NA10076 essence MSD8360

Updated: May 2018